152 related articles for article (PubMed ID: 31531499)
21. Ultrasound-mediated method for rapid delivery of nano-particles into cells for intracellular surface-enhanced Raman spectroscopy and cancer cell screening.
Feng S; Li Z; Chen G; Lin D; Huang S; Huang Z; Li Y; Lin J; Chen R; Zeng H
Nanotechnology; 2015 Feb; 26(6):065101. PubMed ID: 25598539
[TBL] [Abstract][Full Text] [Related]
22. In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.
Yosef HK; Mavarani L; Maghnouj A; Hahn S; El-Mashtoly SF; Gerwert K
Anal Bioanal Chem; 2015 Nov; 407(27):8321-31. PubMed ID: 26168967
[TBL] [Abstract][Full Text] [Related]
23. A high-throughput serum Raman spectroscopy platform and methodology for colorectal cancer diagnostics.
Jenkins CA; Jenkins RA; Pryse MM; Welsby KA; Jitsumura M; Thornton CA; Dunstan PR; Harris DA
Analyst; 2018 Dec; 143(24):6014-6024. PubMed ID: 30398225
[TBL] [Abstract][Full Text] [Related]
24. Panitumumab safety for treating colorectal cancer.
Stremitzer S; Sebio A; Stintzing S; Lenz HJ
Expert Opin Drug Saf; 2014 Jun; 13(6):843-51. PubMed ID: 24766434
[TBL] [Abstract][Full Text] [Related]
25. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
Graham CN; Maglinte GA; Schwartzberg LS; Price TJ; Knox HN; Hechmati G; Hjelmgren J; Barber B; Fakih MG
Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Rivera F; Valladares M; Gea S; López-Martínez N
J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
[TBL] [Abstract][Full Text] [Related]
27. Pseudo-HE images derived from CARS/TPEF/SHG multimodal imaging in combination with Raman-spectroscopy as a pathological screening tool.
Bocklitz TW; Salah FS; Vogler N; Heuke S; Chernavskaia O; Schmidt C; Waldner MJ; Greten FR; Bräuer R; Schmitt M; Stallmach A; Petersen I; Popp J
BMC Cancer; 2016 Jul; 16():534. PubMed ID: 27460472
[TBL] [Abstract][Full Text] [Related]
28. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
Satake H; Tsuji A; Nakamura M; Ogawa M; Kotake T; Hatachi Y; Yasui H; Takagane A; Okita Y; Nakamura K; Onikubo T; Takeuchi M; Fujii M
Int J Clin Oncol; 2018 Jun; 23(3):490-496. PubMed ID: 29464396
[TBL] [Abstract][Full Text] [Related]
30. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
Freeman DJ; Juan T; Reiner M; Hecht JR; Meropol NJ; Berlin J; Mitchell E; Sarosi I; Radinsky R; Amado RG
Clin Colorectal Cancer; 2008 May; 7(3):184-90. PubMed ID: 18621636
[TBL] [Abstract][Full Text] [Related]
31. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
32. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
[TBL] [Abstract][Full Text] [Related]
33. High-throughput screening Raman microspectroscopy for assessment of drug-induced changes in diatom cells.
Rüger J; Mondol AS; Schie IW; Popp J; Krafft C
Analyst; 2019 Aug; 144(15):4488-4492. PubMed ID: 31287453
[TBL] [Abstract][Full Text] [Related]
34. High-throughput label-free molecular fingerprinting flow cytometry.
Hiramatsu K; Ideguchi T; Yonamine Y; Lee S; Luo Y; Hashimoto K; Ito T; Hase M; Park JW; Kasai Y; Sakuma S; Hayakawa T; Arai F; Hoshino Y; Goda K
Sci Adv; 2019 Jan; 5(1):eaau0241. PubMed ID: 30746443
[TBL] [Abstract][Full Text] [Related]
35. Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC.
McGregor M; Price TJ
Future Oncol; 2018 Oct; 14(24):2437-2459. PubMed ID: 29737864
[TBL] [Abstract][Full Text] [Related]
36. Effective panitumumab treatment in patients with heavily pre-treated metastatic colorectal cancer: a case series.
Tzovaras AA; Karagiannis A; Margari C; Barla G; Ardavanis A
Anticancer Res; 2011 Mar; 31(3):1033-7. PubMed ID: 21498734
[TBL] [Abstract][Full Text] [Related]
37. Characterizing variability of in vivo Raman spectroscopic properties of different anatomical sites of normal colorectal tissue towards cancer diagnosis at colonoscopy.
Bergholt MS; Zheng W; Lin K; Wang J; Xu H; Ren JL; Ho KY; Teh M; Yeoh KG; Huang Z
Anal Chem; 2015 Jan; 87(2):960-6. PubMed ID: 25495077
[TBL] [Abstract][Full Text] [Related]
38. A single-cell Raman-based platform to identify developmental stages of human pluripotent stem cell-derived neurons.
Hsu CC; Xu J; Brinkhof B; Wang H; Cui Z; Huang WE; Ye H
Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18412-18423. PubMed ID: 32694205
[TBL] [Abstract][Full Text] [Related]
39. Spotlight on panitumumab in metastatic colorectal cancer.
Keating GM
BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
[TBL] [Abstract][Full Text] [Related]
40. Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
Han van Krieken J; Kafatos G; Bennett J; Mineur L; Tomášek J; Rouleau E; Fabian P; De Maglio G; García-Alfonso P; Aprile G; Parkar P; Downey G; Demonty G; Trojan J
BMC Cancer; 2017 Nov; 17(1):798. PubMed ID: 29183279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
